RnRMarketResearch.com adds “Dengue – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Dengue’s therapeutic pipeline.

Dallas, TX -- (SBWire) -- 10/29/2014 --This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Dengue fever also known as breakbone fever, is a mosquito-borne tropical disease caused by the dengue virus. Symptoms include fever, headache, muscle and joint pains, and a characteristic skin rash that is similar to measles. In a small proportion of cases the disease develops into the life-threatening dengue hemorrhagic fever, resulting in bleeding, low levels of blood platelets and blood plasma leakage, or into dengue shock syndrome, where dangerously low blood pressure occurs.

Complete Report Available @ http://www.rnrmarketresearch.com/dengue-pipeline-review-h2-2014-market-report.html.

Dengue is transmitted by several species of mosquito within the genus Aedes, principally A. aegypti. The virus has five different types; infection with one type usually gives lifelong immunity to that type, but only short-term immunity to the others. Subsequent infection with a different type increases the risk of severe complications. As there is no commercially available vaccine, prevention is sought by reducing the habitat and the number of mosquitoes and limiting exposure to bites.

Dengue - Companies Involved in Therapeutics Development:

United Therapeutics Corporation; GlaxoSmithKline plc; Merck & Co., Inc.; Takeda Pharmaceutical Company Limited; FIT Biotech Oyj; Biological E. Limited; Biotron Limited; Sarepta Therapeutics, Inc.; Medivir AB; BioDiem Ltd; NanoViricides, Inc.; SIGA Technologies, Inc. (Inactive); Panacea Biotec Limited; Bharat Biotech International Limited; TechnoVax, Inc.; MacroGenics, Inc.; PTC Therapeutics, Inc.; Kineta, Inc.; Immunovaccine, Inc.; VaxInnate Corporation; Janssen Pharmaceuticals, Inc.; Cocrystal Pharma, Inc.
PaxVax; RFS Pharma, LLC; AltraVax Inc.; Visterra, Inc.; Arbovax, Inc.; Sanofi Pasteur SA; Themis Bioscience GmbH; Agilvax, Inc.; Humabs BioMed SA; Codagenix, Inc.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235019.

Dengue Drug Profiles:
dengue vaccine [types 1,2,3,4] (tetravalent); TAK-003; dengue vaccine 3; dengue vaccine {rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30 }(tetravalent); celgosivir hydrochloride; dengue vaccine 4; V-180; DNA Vaccine for Dengue; DENV-1 PIV; UV-4B; modipafant; ST-148; DengueCide; TVX-005; dengue vaccine (DEN-2); AVI-6006; dengue vaccine; DV-2-G460P; ST-610; rOAS; dengue vaccine (tetravalent); GREDEN/V1-4; VIS-513

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope
- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Therapeutics Drugs Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .